China Medipharm Insights - December 2000

 

Regular Price: USD 1,000

Special Price USD 700

30% OFF

* Required Fields

Regular Price: USD 1,000

Special Price USD 700

PAY BY INVOICE

Be the first to review this product

Table of Contents

China Medipharm Insights - December 2000, China Medipharm InsightsChina Hepatitis Therapy Market AnalysisThe Market Grew at 11.3 Percent in 1999 to US$ 228 million Demand AnalysisMarket Segment AnalysisCompetitive AnalysisDrug ConsumptionConsumption of Anti-infectives in Hospitals From 1992 to 1999Anti-tumor Drug Consumption at Shanghai Ruijin HospitalCompany ProfilesGuangzhou Pharma Targets Gene DrugsBaiyunshan Joins Hands with Peking UniversityRoche New Asiatic Vitamin B6 Production Line CompletedNorth China Becomes National High Tech Industrial BaseNorth China Group Expands Isoflavone ProductionShenzhen Zhuohai Steps into Pharma SectorHarbin Pharma Group Saw 60 Percent Growth in Sales in Jan-OctCooperation Boosts Shandong Xincoshat Pharma Huadong Pharma to Suffer Profit LossXinhua-Chemferm Expands RapidlyChongqing Medical Co. Ltd. FlourishesDalian Meiluo Raises Funds from Stock MarketZhejiang Yingte Medical Trading Co. Strives ForwardAnhui Huayuan Biopharmaceutical Co. EstablishedTsinghua Ziguang Pharma Ally FormedChongqing Sine Oriental Pharma EstablishedKunming Pharma Raises Funds in Stock MarketInner Mongolia and Shanghai to Boost Commercialization of Gene Engineering VaccinesFeature: A War of Anti-cold Drugs Breaks Out Upon SDA’S Ban on PPA-containing DrugsSDA Bans Anti-cold Drugs with PPA IngredientTianjin SK & F; Major Sufferer of PPA Event; Is Still Fully Confident in OTC Market StrategyAnti-cold Drug Makers Strive to Replace Tianjin SmithKline & FrenchDoubt over Anti-cold Chemical Drugs Presents Unexpected Opportunity for Anti-cold TCMs.Product NewsAprovel Cleared for Market by Sanofi-SynthelaboRivastigmine Launched in ChinaFumarate Enters Chinese MarketClass I Anti-hepatitis Baisainuo Completes Phase III Clinical TrialsLiquefied Polio Vaccines DevelopedLosec 10mg Launched by AstraZenecaAnti-AIDS Crixivan and Sustiva LaunchedAniracetam Put into Production at Yabao Pharma Recombinant Human Urine Fibrinokinase Enters Clinical TrialsGenetic Engineering Syphilis Diagnostic Kit DevelopedNorth China Launches Its First OTC DrugXinhua Group Launches New Antibiotic BaihongyouCompound Amino Acid Micropill Capsule Put into ProductionOxaprozin Granted New Drug CertificateChinese-Made Human Insulin MarketedGlucose Puerarin Granted with NDCGanciclovir Passes Expert Panel EvaluationRefined Rutin Put into Operation Anti-tumor Aishengkang MarketedChinese Tibetan Drugs Approved by US FDARegulations & PoliciesMedical Service Charges to Be Standardized NationwideNew Regulation on Drug Administrative Protection IssuedAds for Sexual Function Drugs ProhibitedAnti-fake Drug Campaigns BeginNew Medical Insurance Scheme Starts Out in ShanghaiNews in BriefTCM Exports from Shanghai Ports Climb upPharma Industry Grows in Q1-Q3 2000Drug Price Falls Lead to More Fierce CompetitionExtraordinarily High Drug Price not Effectively ControlledLiaoning Cuts Drug PricesDrug Prices Cut in Gansu ProvinceSichuan Makes Price Cuts on DrugsHubei Initiates Unified Drug ProcurementUnified Drug Procurement Leads to Drug Price Cut in FujianCross Regional Drug Store Chains Start Out in ShandongStem Cell Gene Engineering Industrial Base Set up in TianjinOsteoporosis Prevalent in Women over 45Breast Cancer Increases in ChinaShanghai Zhangjiang Drug Valley Gains High ReturnsChina Makes Progress in Early Diagnosis of Gastric Cancer Designated Medical Insurance Drugstores Open in ShanghaiAdvertisements for Venereal Disease Drugs Banned in Shanghai




Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.